| Bioactivity | hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC50=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells[1]. |
| Target | IC50: 204 nM (VEGFR-2), 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), 75.3 nM (hCA I) |
| In Vivo | hCA/VEGFR-2-IN-2 (compound 8g) |
| Name | hCA/VEGFR-2-IN-2 |
| Formula | C23H26N6O5S |
| Molar Mass | 498.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Saied S, et al. Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. Eur J Med Chem. 2023 Nov 5;259:115707. |